Home › Research › Prevention and risk
[Epidemiology of Alzheimer's disease and other dementias]
Garre-Olmo J.. Revista de neurologia, 2018-06-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Dementia is a clinical syndrome resulting from a number of causations and which is usually accompanied by progressive and diffuse brain dysfunction. The different subtypes are characterised by a clinical picture with common symptoms that differ in terms of their aetiology, age, clinical presentation, clinical course and associated disorders. Aim To present an update on the information available about the descriptive epidemiology of dementia and its main subtypes. Development The main data on prevalence, incidence and mortality were extracted from a literature review. Alzheimer's disease is the most frequent subtype and accounts for 60-80% of all the cases, followed by vascular dementia and other neurodegenerative dementias, such as dementia due to Lewy bodies, the dementia-Parkinson complex and frontotemporal dementia. Other subtypes of dementias present frequencies below 1%, and the epidemiological indicators available are not very robust. Conclusions The prevalence and incidence of dementia increase exponentially from the age of 65 onwards. As a consequence of the progressive ageing of the population and the increase in life expectancy, the number of cases of dementia will rise in the coming decades. Recent studies point to a slight drop in the accumulated risk of dementia adjusted by age groups and sex over the last few decades in some countries. It is possible that by means of primary prevention strategies implemented upon the known risk factors for dementia the burden of dementia on public health will diminish in the future.
What this study adds
Evidence grade: Low
This is a narrative review. This review reports that dementia prevalence and incidence rise sharply from age 65 and will increase as populations age, while some recent studies suggest a slight drop in age- and sex-adjusted risk in some countries. It describes patterns over time and does not test any treatment or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Garre-Olmo, J. (2018). [Epidemiology of Alzheimer's disease and other dementias]. Revista de neurologia. https://doi.org/10.33588/rn.6611.2017519
Vancouver
Garre-Olmo J. [Epidemiology of Alzheimer's disease and other dementias]. Revista de neurologia. 2018. doi:10.33588/rn.6611.2017519. PMID: 29790571.
BibTeX
@article{garreolmo2018-29790571,
author = {Garre-Olmo, J.},
title = {{[Epidemiology of Alzheimer's disease and other dementias]}},
journal = {Revista de neurologia},
year = {2018},
doi = {10.33588/rn.6611.2017519},
pmid = {29790571},
url = {https://doi.org/10.33588/rn.6611.2017519}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Other subtypes of dementias present frequencies below 1%, and the epidemiological indicators available are not very robust.
- Conclusions The prevalence and incidence of dementia increase exponentially from the age of 65 onwards.
- As a consequence of the progressive ageing of the population and the increase in life expectancy, the number of cases of dementia will rise in the coming decades.
- Recent studies point to a slight drop in the accumulated risk of dementia adjusted by age groups and sex over the last few decades in some countries.
- It is possible that by means of primary prevention strategies implemented upon the known risk factors for dementia the burden of dementia on public health will diminish in the future.
Why it matters
This review reports that dementia prevalence and incidence rise sharply from age 65 and will increase as populations age, while some recent studies suggest a slight drop in age- and sex-adjusted risk in some countries. It describes patterns over time and does not test any treatment or prevention.
New to this subject? Start with our plain-English guide: Prevention →
Study details
- Evidence strengthLow
How this study scored 42/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on institution's track record, so that was left out: it earned 41 of the 97 points we could judge it on, which is 42 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Revista de neurologia) |
| Journal's citation record | 0 / 4 | Revista de Neurología: journal h-index 51 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 165 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 16.5 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 4 / 6 | Cited 10.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 2 / 6 | Cited by 7 other studies in this library |
| Still being cited | 3 / 4 | Cited 51 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Josep Garre‐Olmo: h-index 48 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 29790571) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 41 / 97 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 41 of the 97 points we could judge it on is 42 out of 100. |
| Total | 42 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Later studies that cite this one
7 studies in the alzhub library list this one in their references.
Related studies in Prevention and risk from nearby years
Also in Prevention and risk
269 studies in the library are filed under Prevention and risk with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Prevention and risk hub.